ANDA 200158, held by Sandoz. Diclofenac Sodium; Misoprostol.
As of Nov 21, 2026, ANDA 200158 (Diclofenac Sodium and Misoprostol), held by Sandoz, was first approved by FDA on May 9, 2013, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 9, 2013 | Original application | Approved | None posted |
| Diclofenac Sodium and Misoprostol50MG;0.2MG · tablet, delayed release;oral | Diclofenac Sodium; Misoprostol | Discontinued |
| Diclofenac Sodium and Misoprostol75MG;0.2MG · tablet, delayed release;oral | Diclofenac Sodium; Misoprostol | Discontinued |
| May 19, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| May 19, 2023 | Supplement 8Labeling · Standard review | Approved | None posted |
| May 19, 2023 | Supplement 9Labeling · Standard review | Approved | None posted |
| May 19, 2023 | Supplement 10Labeling · Standard review | Approved | None posted |
| May 19, 2023 | Supplement 11Labeling · Standard review | Approved | None posted |
| May 19, 2023 | Supplement 12Labeling · Standard review | Approved | None posted |
| May 19, 2023 | Supplement 13Labeling · Standard review | Approved | None posted |
| May 19, 2023 | Supplement 14Labeling · Standard review | Approved | None posted |
| May 9, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters